Loading...
XSHG
688366
Market cap816mUSD
Jul 10, Last price  
30.96
1D
1.21%
1Q
-20.68%
IPO
-76.31%
Name

Shanghai Haohai Biological Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:688366 chart
P/E
P/S
EPS
0.61
Div Yield, %
3.64%
Shrs. gr., 5y
5.57%
Rev. gr., 5y
13.06%
Revenues
2.45b
-8.71%
303,065,000401,088,000515,940,000663,917,000851,157,0001,344,856,0001,545,824,0001,595,498,0001,324,427,0001,750,116,0002,103,438,0002,634,910,0002,679,667,0002,446,306,000
Net income
245m
-41.85%
113,942,000141,521,000183,582,000273,474,000305,052,000372,415,000414,540,000370,779,000230,072,000352,234,000180,470,000416,121,000420,447,000244,509,783
CFO
629m
-3.09%
118,420,000146,906,000141,993,000268,511,000254,485,000343,059,000391,284,000348,911,000262,073,000342,286,000231,296,000634,450,000648,572,000628,501,638
Dividend
Oct 10, 20240.4 /sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.
IPO date
Apr 30, 2015
Employees
2,123
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT